---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-022266"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T09:21:39.023474+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Janux Therapeutics suspends ATM equity offering program

## Summary
- Delivered written notice to BofA on Feb 28, 2024 suspending the ATM prospectus supplement.
- No further sales of common stock under the Sales Agreement until a new prospectus supplement is filed.
- Sales Agreement remains in full force and effect; suspension does not terminate it.

## SEC filing metadata
- accession: 0000950170-24-022266
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017024022266/0000950170-24-022266-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017024022266/janx-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-022266
- JSON: https://secwatch.observer/filing/0000950170-24-022266.json
- Plain text: https://secwatch.observer/filing/0000950170-24-022266.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.